Autentificare
NeuroPsy InfoHubÎnțelege · Sprijin · ProgresCere sprijin
← Toate temele

Scleroză multiplă

Scleroza multiplă și viața cu aceasta.

71 de articole
← Toate secțiunile

Studii și știri

PublicToțiPentru oricineSpecialiști
VârstăToate vârsteleCopiiTineriAdulțiVârstnici
StudiuScleroză multiplăÎncredere înaltă20.06.2026

Impaired Temporal Processing in Multiple Sclerosis: Links to Basal Ganglia Damage and Fatigue

This study demonstrates that people with MS show measurable deficits in both perceptual timing (beat detection) and motor timing (finger-tapping consistency) compared to normative data, attributed to basal ganglia microstructural damage. These timing impairments correlate significantly with disease progression and fatigue severity, suggesting temporal processing measures could serve as objective biomarkers for MS disease activity.

StudiuScleroză multiplăÎncredere înaltă20.06.2026

Multiple Sclerosis Agents: Disease-Modifying and Symptomatic Therapies

Multiple sclerosis is a chronic autoimmune demyelinating disorder of the central nervous system that typically presents between ages 20-40, with higher prevalence in women and Northern European/North American populations. Current therapeutic approaches include disease-modifying immunomodulatory agents (interferons, glatiramer acetate, monoclonal antibodies, fumarates, and others) and symptomatic treatments to manage disease progression and disability.

StudiuScleroză multiplăÎncredere bună19.06.2026

Intrathecal IgM Species as Potential Prognostic Biomarkers in Relapsing-Remitting Multiple Sclerosis

This retrospective study examined whether specific IgM antibody markers in cerebrospinal fluid could predict disease progression in 37 relapsing-remitting MS patients over up to 17 years. Patients with both oligoclonal IgM bands and anti-S-nitrosylated protein IgM showed more aggressive disease, while those lacking both markers had more benign outcomes, suggesting these biomarkers may help guide clinical management decisions.

StudiuScleroză multiplăÎncredere bună19.06.2026

Structure-Function Multilayer Network Integration and Cognition in Multiple Sclerosis

This study examined how integrated structural and functional brain networks in the frontoparietal region relate to cognitive performance in 780 people with relapsing-remitting MS. Higher multilayer network centrality and single-layer network parameters showed weak associations with cognitive test performance, but findings were not reproducible across different brain atlases, limiting their practical significance.

StudiuScleroză multiplăÎncredere bună19.06.2026

Effect of Brain Gym on Cognition, Manual Dexterity and Bimanual Coordination in Multiple Sclerosis Patients

This randomized controlled trial compared educational kinesiology (brain gym) combined with conventional physical therapy against conventional therapy alone in 36 MS patients with mild cognitive impairment. The study group receiving brain gym showed significant improvements in cognitive function and hand coordination measures assessed via RehaCom and Purdue Pegboard tests over 4 weeks of treatment.

StudiuScleroză multiplăÎncredere bună19.06.2026

Psychological resilience predicts medication adherence in multiple sclerosis

A study of 165 people with relapsing-remitting multiple sclerosis found that psychological resilience independently predicts better medication adherence to disease-modifying therapies, even after accounting for depression, anxiety, stress, quality of life, and disability level. Those with good adherence showed significantly higher resilience scores and lower psychological distress compared to poorly adherent patients.

StudiuScleroză multiplăÎncredere înaltă19.06.2026

Defining Activity-Based Subgroups in Multiple Sclerosis: A Review and Framework Proposal

This systematic review examines how multiple sclerosis is stratified into activity-based subgroups across clinical trials and regulatory guidance, identifying significant inconsistencies in terminology and definitions for 'active', 'highly active', and 'rapidly evolving severe' disease. The authors propose a standardized framework to improve consistency in treatment decision-making and health technology assessments.

StudiuScleroză multiplăÎncredere înaltă19.06.2026

Cognition in Multiple Sclerosis in the Modern Diagnostic and Treatment Era

This study re-evaluates the classical model that processing speed is the primary cognitive deficit in MS by examining patients diagnosed and treated in the modern era (2001-2025). Early relapsing-remitting MS patients showed memory deficits but normal cognitive speed, contradicting the traditional speed-centric model and suggesting disease-modifying therapies may have altered the cognitive profile of MS.

StudiuScleroză multiplăÎncredere înaltă19.06.2026

Impaired Cerebrovascular Reactivity Associated with Disability and Cognitive Performance in Relapsing-Remitting Multiple Sclerosis

This cross-sectional study found that patients with relapsing-remitting MS have reduced cerebrovascular reactivity (measured by Breath-Holding Index) compared to healthy controls, independent of demographic factors. Lower cerebrovascular reactivity was independently associated with greater neurological disability and slower processing speed on cognitive testing.

StudiuScleroză multiplăÎncredere înaltă19.06.2026

Relapsing-remitting multiple sclerosis in a patient with Huntington's disease

A woman in her 50s with confirmed Huntington's disease developed right-sided sensory symptoms and was diagnosed with relapsing-remitting MS based on MRI findings of demyelinating lesions, oligoclonal bands in cerebrospinal fluid, and McDonald diagnostic criteria. The case underscores the importance of evaluating new neurological symptoms in patients with neurodegenerative conditions rather than attributing all manifestations to a single disease process.

StudiuScleroză multiplăÎncredere înaltă19.06.2026

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanism and Clinical Evidence

BTK inhibitors represent an emerging oral therapeutic class for MS that can target both adaptive and innate immune pathways, with some agents crossing the blood-brain barrier to address progressive MS pathology resistant to current treatments. Phase 2 and 3 trial data show promise, particularly for agents like tolebrutinib in secondary progressive MS disability progression.

StudiuScleroză multiplăÎncredere bună19.06.2026

COVID-19 and Radiological Progression of Multiple Sclerosis: A Matched Cohort Study

This retrospective study compared brain MRI changes between 34 MS patients who tested positive for SARS-CoV-2 and 67 matched negative controls over approximately two years. No significant differences were found between groups in new lesions, enlarging lesions, gadolinium-enhancing lesions, or brain volume loss, suggesting COVID-19 does not accelerate radiological MS progression.

StudiuScleroză multiplăÎncredere înaltă19.06.2026

Insights and Challenges on Animal Models for Progressive Multiple Sclerosis

This article examines the use of animal models in studying progressive forms of multiple sclerosis, discussing both the insights gained and the methodological challenges encountered. It addresses how preclinical animal research contributes to understanding MS pathophysiology while acknowledging limitations in translating findings to human disease.

StudiuScleroză multiplăÎncredere înaltă19.06.2026

Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis

This large pooled analysis of 4,241 RRMS patients from phase 3 trials examined how chronological age influences brain volume changes over 96 weeks of follow-up. Older participants showed lower baseline brain volumes but exhibited significantly slower atrophy rates during follow-up compared to younger patients, particularly in the thalamus.

StudiuScleroză multiplăÎncredere înaltă19.06.2026

Treatment of Multiple Sclerosis: Evidence-Based Approaches to Relapses and Disease-Modifying Therapy Selection

The article reviews evidence-based management of MS relapses using high-dose corticosteroids while distinguishing true MS-related symptoms from transient worsening caused by systemic factors. It emphasizes shared decision-making for selecting higher-efficacy therapies or escalation strategies, with appropriate screening and ongoing safety monitoring, noting that benefits vary between relapsing and progressive MS presentations.

StudiuScleroză multiplăÎncredere înaltă19.06.2026

Incidence of Multiple Sclerosis in Switzerland: Results from the Swiss Multiple Sclerosis Registry (2017-2021)

This epidemiological study estimated the annual MS incidence in Switzerland at 7.7 per 100,000 inhabitants (approximately 663 cases annually) from 2017-2021, with stable rates across the study period and higher incidence in women than men. Peak incidence occurred in the 30-35 age group for women and 35-40 for men, with most newly diagnosed individuals receiving disease-modifying therapies.